Study of Prostate Cancer in Black and White U.S. Veterans

This study has been completed.
Sponsor:
Information provided by:
Department of Veterans Affairs
ClinicalTrials.gov Identifier:
NCT00007540
First received: December 29, 2000
Last updated: January 20, 2009
Last verified: February 2003
  Purpose

Prostate cancer is diagnosed in approximately 334,500 men each year and accounts for nearly 41,800 deaths in the United States. Prostate cancer is the leading cancer affecting veterans and the second leading cancer among all Americans. The causes of prostate cancer and, particularly, the reasons for the unusually high incidence rates in African-Americans remain obscure. Dietary factors likely play a role in fatal cases, while hormones are also important in regulating prostate cancer growth. Dr. Charles Huggins recognized this effect in the 1940?s, with androgen deprivation remaining as the cornerstone of therapy for advanced disease. Despite the strong circumstantial evidence, neither epidemiologic studies nor basic sciences have produced clear insight into the etiologic role of hormones. However, recent observations regarding androgen receptor gene polymorphisms and their relation to endocrine expression and prostate cancer risk may be providing important clues as to how an etiologic role might be mediated at the molecular level. Thus, it is important to attempt to identify genetic markers of high-risk cancer patients for necessary screening and counseling efforts.


Condition
Prostate Cancer
Prostatic Neoplasms

Study Type: Observational
Official Title: Study of Prostate Cancer in Black and White U.S. Veterans

Resource links provided by NLM:


Further study details as provided by Department of Veterans Affairs:

Study Start Date: April 1998
Estimated Study Completion Date: September 2000
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Veterans who undergo prostate biopsy where biopsy results are positive or PSA less than 10Ng/ml.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00007540

Locations
United States, Illinois
Vamc - Chicago-Lakeside, Il
Chicago, Illinois, United States, 60611
Sponsors and Collaborators
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00007540     History of Changes
Other Study ID Numbers: 709D
Study First Received: December 29, 2000
Last Updated: January 20, 2009
Health Authority: United States: Federal Government

Keywords provided by Department of Veterans Affairs:
Prostate cancer
CAG repeat sequence

Additional relevant MeSH terms:
Neoplasms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Genital Diseases, Male
Prostatic Diseases
Hydroquinone
Radiation-Protective Agents
Protective Agents
Physiological Effects of Drugs
Pharmacologic Actions
Antioxidants
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on April 17, 2014